I'd like to see management give some more clarity around their approach to 2RT and the partnership. E&P are still very bullish on it, and view the probability of a successful clinical trial as very high, but they can't value it until there's more clarity around the timeline. Obviously iTrack Advance is the main focus (as it should be), but clarity around 2RT could easily be a catalyst for a major rerate.
I'd like to see management give some more clarity around...
-
- There are more pages in this discussion • 2,139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.0¢ | $24.11K | 132.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 137086 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 14.41pm 04/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |